Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMXT 1501 + DFMO in advanced solid tumors
NCT03536728Phase 1Completed
- Sponsor
- Aminex Therapeutics
- Start
- Jun 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AMXT-1501 in solid tumor (3 arms), sponsored by Aminex Therapeutics. Primary endpoints: Dose Limiting Toxicities at 2 years and Safety and Tolerability at 2 years. Started Jun 2018; status: completed.
02
Drugs
AMXT-1501
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03536728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536728.